Why the Plastic Health Research Act is the right next step 

Effective microplastics policy starts with good data

If passed, the Plastic Health Research Act (PHRA, H.R.4903), introduced by Reps. Haley Stevens (D-Mich.) and Frank Lucas (R-Okla.), would enable credible, coordinated research that can guide smart microplastics policy. By raising the bar for evidence, it gives agencies, states, public health experts, and manufacturers a shared baseline to work from, which would be a significant move in the right direction.

Core elements of the PHRA  

The PHRA would create a federal approach to microplastics research. If enacted, the PHRA would direct the Department of Health and Human Services (HHS) to coordinate a multi-agency research program on microplastics and health that would include grants and Centers of Excellence. It would prioritize methods development, validated reference materials, and comparable analytics, while authorizing sustained funding to close the most important microplastics research gaps. This type of coordinated federal program would be more effective than the current research patchwork, because under the former, studies could be compared, combined, and reproduced rather than continuing to talk past each other.

Now is the right time to pass the PHRA 

At present, states such as California are writing recycling, labeling, and disclosure rules, creating de-facto policies for the entire country, given the size of the state’s economy. Federal agencies are considering microplastics monitoring programs and data standards. Companies are investing in materials, design changes, and recovery technologies. And all of this depends on precise and accurate definitions and reliable methods to measure the presence of microplastics, where they come from, how people are exposed, and whether they pose risks which are currently lacking. 

A shared research agenda, which the PHRA makes possible, would help standardize measurement, map exposure with transparency, and tie policy to sound evidence. In doing so, this approach would reduce the risks of overregulating low-impact sources, underregulating higher-impact sources, and eroding public trust.

The PHRA would enable early measures of success 

With passage of the PHRA, early wins would be concrete and visible. The following deliverables can be prioritized immediately after enactment would begin to improve the science on which to base policy decisions and potential mitigation measures: 

• Reproducible research methods: the development and deployment of standard scientific definitions, reference materials, and validated testing methods for complex microplastics and nanoplastics research to improve quality and comparability of results across studies. 
• Exposure map: the generation of a clear view of major exposure pathways, sensitive subpopulations, and key uncertainties, with a plan to close the most important gaps. 
• Transparency: the publication of a public dashboard that tracks funded studies, methods, and interim findings so stakeholders can follow progress. 

The PHRA is better than other microplastic bills  

The Microplastics Safety Act (S. 2353, H.R. 4486) a separate bill sponsored by Sen. Jeff Merkley (D-Ore.) and Rep. Scott Perry (R-Pa.) would direct the Food and Drug Administration (FDA) to study microplastics exposure in food and water. However, this bill directs the provision of a report to Congress within one year of enactment with findings and recommendations. That focus is useful, but it’s narrow, duplicative, and time limited (U.S. FDA, 2024). Further, it doesn’t create a multi-agency program, which is critical, or set out a plan to standardize methods across media, and it centers on food and water rather than the full exposure picture.  In short, the bill yields a single report, not a durable federal research framework on an emerging area of science and policy. 

By contrast, the PHRA builds a coordinated approach. It directs HHS to work with the FDA, EPA, NOAA, NIST, and NIEHS; funds methods and reference materials; and stands up grants and centers so work continues beyond a single report.

If the goal is to align definitions, compare results, and regulate what the evidence supports, a one-year study at a single agency will not get us there. A cross-agency program with sustained funding will. In doing so, the PHRA lays the groundwork for smarter policymaking, turning coordinated science into coordinated action.

Good science should steer smart policy

With consistent definitions and harmonized methods, the PHRA can help align the scientific community to fill knowledge gaps through reproducible microplastics research that builds a coherent and collaborative body of evidence on microplastics. Shared, evidence-driven definitions and methods anchor compliance, guide investment, and drive smarter, more effective outcomes.  

Once that scientific foundation is established, it can inform microplastics policy, helping decision-makers focus resources where they have the greatest impact and ensuring regulations are grounded in sound science.

The bottom line: Measure twice, take action once 

Passage of the PHRA would align methods, map exposure, and design interventions that deliver measurable gains. The fastest path to durable policy on microplastics is a stronger evidence base that is shared, transparent, and built to guide real-world decisions. The Plastic Health Research Act is the right next step.